Venus Medtech (Hangzhou) Inc.
Research Venus Medtech (Hangzhou) Inc. (2500.HK) on Bullrun: market cap HKD 472.93M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2500.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryMedical Devices
- CurrencyHKD
- Market capHKD 472.93M
- Financial periodFY2025
- RevenueCNY 306.79M
- Revenue growth-34.8%
- Net income-CNY 407.69M
- Free cash flow-CNY 332.12M
- Gross margin69.0%
Valuation Snapshot
latest market cap is HKD 472.93M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 306.79M | -CNY 407.69M | -CNY 332.12M | 69.0% | -0.93 | CNY 158.34M | CNY 62.13M | CNY 1.76B |
| FY2024 | CNY 470.83M | -CNY 714.31M | -CNY 17.82M | 78.1% | -1.63 | CNY 298.04M | CNY 369.09M | CNY 2.21B |
| FY2023 | CNY 491.37M | -CNY 703.75M | -CNY 872.93M | 79.2% | -1.65 | CNY 774.40M | CNY 826.19M | CNY 2.92B |
| FY2022 | CNY 406.46M | -CNY 1.06B | -CNY 908.23M | 77.3% | -2.42 | CNY 1.88B | CNY 899.64M | CNY 3.61B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 472.93M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Venus Medtech (Hangzhou) Inc.
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Venus Medtech (Hangzhou) Inc.'s market cap?
Venus Medtech (Hangzhou) Inc.'s market capitalization is HKD 472.93M.
What does Venus Medtech (Hangzhou) Inc. do?
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis.